Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effects of Sitagliptin on Glycemic Control and Lipoprotein Metabolism (GLORIA)

Trial Profile

Effects of Sitagliptin on Glycemic Control and Lipoprotein Metabolism (GLORIA)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 14 Aug 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sitagliptin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms GLORIA
  • Most Recent Events

    • 09 Jun 2015 Primary endpoint Biomarker levels has been met as per abstract presented at 75th Annual Scientific Sessions of the American Diabetes Association.
    • 09 Jun 2015 Results presented at the 75th Annual Scientific Sessions of the American Diabetes Association.
    • 02 Jun 2015 Status changed from recruiting to completed as reported by UMIN record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top